Cephalon settles Fentora patent fight with Barr; FDA chief defends decision against H1N1 adjuvants;

> Cephalon has come to an agreement to settle its patent infringement dispute with Barr Pharmaceuticals over the pain drug Fentora. Report

> The head of the FDA defended the agency's decision not to use an additive that could have stretched swine flu vaccine supplies, adding that doses should be coming more regularly. Report

> Shire reported positive findings from its Vyvanse late-stage trials, indicating the drug significantly improved frequent changes in emotions or mood in children with ADHD. Report

> Serbia signed a contract for the purchase of 3 million doses of new flu vaccinces from Novartis two days after the authorities declared a flu epidemic. Report

> New results from a survey of 1,122 post-menopausal women in Asia found that nearly half did not know whether they had osteoporosis despite being hospitalized with a fragility fracture. Report

> Much of what Americans do in the name of warding off cancer has not been shown to help, yet the few medicines proved to deter cancer are widely ignored. Report

Biotech News

> Here's some good biotech job news for a change: Talecris Biotherapeutics, which recently launched a successful IPO, announced that it will create 259 jobs as it plots the $269 million expansion of its manufacturing facility, increasing the 1,800-person workforce it already has in the Research Triangle Park, NC area. Report

> Saying it needs more time to evaluate pharmacological data, the FDA has extended the review period for Cadence Pharmaceuticals' Acetavance until February 2010. Report

> Alnylam Pharmaceuticals is one of the original pioneers in the biotech industry, widely recognized for its role in establishing RNA interference as one of the most promising fields in drug discovery. Report

> Germany's Boehringer Ingelheim has high hopes for its experimental female libido booster flibanserin. The treatment, which addresses hypoactive sexual desire disorder, or HSDD, has completed Phase III trials; results from those studies will be discussed at a conference on sexual dysfunction next week. Report

> Sweden's BioInvent International has inked a license and discovery agreement with Japanese drugmaker Daiichi Sankyo to develop therapeutic antibodies against multiple targets. Report

And Finally... Harrison Ford plays the scientist who discovered the Pompe disease drug Myozyme in the forthcoming feel-good pharma movie Extraordinary MeasuresReport

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.